Immuneering Corp (IMRX): who owns it and who trades it
As of Nov 16, 2026, IMRX insiders reported 8 purchases worth $360K in the last 12 months. The largest buyer was Thomas J. Schall (Director), with $101K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Immuneering
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMRX
112 funds and institutions reported IMRX shares worth $172M at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $48.4M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.70M | – | $48.4M | +0% |
| BlackRock, Inc. | 4.37M | – | $21.8M | +190% |
| Sanofi | 2.71M | – | $13.5M | No change |
| Vanguard Capital Management LLC | 2.29M | – | $11.4M | -0% |
| T. Rowe Price Associates | 1.94M | – | $9.7M | +6% |
| Geode Capital Management, LLC | 1.37M | – | $6.8M | +115% |
| State Street Corp | 1.00M | – | $5M | +273% |
| DCF Advisers, LLC | 790,000 | – | $3.9M | +458% |
| Marshall Wace, LLP | 731,897 | – | $3.7M | -63% |
| Connor, Clark & Lunn Investment Management Ltd. | 601,255 | – | $3M | +50% |
| Alethea Capital Management, LLC | 472,935 | – | $2.4M | +1962% |
| Summit Financial, LLC | 452,264 | – | $2.3M | +20% |
| UBS Group AG | 448,857 | – | $2.2M | +19% |
| Nuveen, LLC | 438,362 | – | $2.2M | New |
| Northern Trust Corp | 436,992 | – | $2.2M | +271% |
| Levin Capital Strategies, L.P. | 414,000 | – | $2.1M | +4040% |
| Citadel Advisors LLC | 386,411 | – | $1.9M | -14% |
| Vanguard Fiduciary Trust Co | 360,764 | – | $1.8M | +12% |
| Vanguard Portfolio Management LLC | 359,085 | – | $1.8M | New |
| Gsa Capital Partners LLP | 343,303 | – | $1.7M | +347% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMRX insiders reported $360K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Andrew Gengos | CFO | Purchase | 25,000 | $3.58 | $89.5K | Form 4 |
| Jun 23, 2026 | Benjamin J. Zeskind | CEO | Purchase | 2,400 | $4.56 | $10.9K | Form 4 |
| Jun 15, 2026 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Purchase | 6,035 | $4.15 | $25K | Form 4 |
| Jan 16, 2026 | Harold Eugene Brakewood | Chief Business Officer | Purchase | 5,250 | $4.76 | $25K | Form 4 |
| Jan 15, 2026 | Thomas J. Schall | Director | Purchase | 21,645 | $4.67 | $101K | Form 4 |
| Jan 15, 2026 | Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | Purchase | 2,298 | $4.57 | $10.5K | Form 4 |
| Jan 13, 2026 | Leah R Neufeld | CHIEF PEOPLE OFFICER | Purchase | 2,626 | $4.15 | $10.9K | Form 4 |
| Jan 12, 2026 | Peter Feinberg | Director | Purchase | 20,000 | $4.35 | $87K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Thomas J. Schall | Director | $101K | – | Jan 15, 2026 |
| Andrew Gengos | Chief Financial Officer | $89.5K | – | Nov 13, 2026 |
| Peter Feinberg | Director | $87K | – | Jan 12, 2026 |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | $35.5K | – | Jun 15, 2026 |
| Harold Eugene Brakewood | Chief Business Officer | $25K | – | Jan 16, 2026 |
| Benjamin J. Zeskind | PRESIDENT AND CEO, Director | $10.9K | – | Jun 23, 2026 |
| Leah R Neufeld | CHIEF PEOPLE OFFICER | $10.9K | – | Jan 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMRX short interest
14.60M IMRX shares are sold short. Over the last 12 reports the number of shares short went up 48%.
As of Oct 30, 2026, 14.60M IMRX shares were sold short, down 10.6% from the report before. At the average daily volume of 760,062 shares, buying them all back would take about 19.2 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 14.60M | – | -11% | 760,062 | 19.2 |
| Oct 15, 2026 | 16.32M | – | +5% | 801,860 | 20.4 |
| Sep 30, 2026 | 15.49M | – | -0% | 639,765 | 24.2 |
| Sep 15, 2026 | 15.55M | – | +5% | 756,551 | 20.6 |
| Aug 31, 2026 | 14.84M | – | +3% | 547,452 | 27.1 |
| Aug 14, 2026 | 14.43M | – | -6% | 745,013 | 19.4 |
| Jul 31, 2026 | 15.40M | – | +1% | 755,903 | 20.4 |
| Jul 15, 2026 | 15.21M | – | +1% | 926,955 | 16.4 |
| Jun 30, 2026 | 15.03M | – | +7% | 1.97M | 7.6 |
| Jun 15, 2026 | 14.03M | – | +10% | 2.27M | 6.2 |
| May 29, 2026 | 12.72M | – | +29% | 2.57M | 5.0 |
| May 15, 2026 | 9.89M | – | +4% | 663,643 | 14.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immuneering company events
Immuneering filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026LeadershipThe Board of Directors of Immuneering Corporation appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director. Filing
- Oct 29, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 15, 2026LeadershipThe Board of Directors of Immuneering Corporation appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually… Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AnnouncementImmuneering Corporation announced updated data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or "MEK") inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel in first-line… Filing
- May 15, 2026ResultsReleased financial results. Filing
- Mar 6, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementImmuneering Corporation announced updated interim data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or MEK) inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel in first-line… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immuneering financials
Famous investors that hold IMRX
3 of the 50 well-known investors we track reported holding IMRX in their latest 13F filing. The largest position is Ken Fisher's, worth $475K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 115,954 | $475K | 0.0% | +31% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 89,895 | $368K | 0.0% | -77% |
| Israel Englander · Millennium Management | Q3 2026 | 43,712 | $179K | 0.0% | -87% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Immuneering Corp (IMRX) stock
Who owns the most IMRX stock?
The largest reported owner of Immuneering Corp (IMRX) is FMR LLC (Fidelity). In total, 112 funds and institutions reported holding IMRX at the end of Q2 2026. See the largest owners.
Are IMRX insiders buying or selling?
In the last 12 months, IMRX insiders reported 8 open-market purchases worth $360K and no sales. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in IMRX?
As of Oct 30, 2026, 14.60M IMRX shares were sold short, down 10.6% from the report before. At the average daily volume of 760,062 shares, buying them all back would take about 19.2 trading days (days to cover). See the history.
Which famous investors hold IMRX?
3 of the 50 well-known investors we track reported IMRX in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $475K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.